ClotCare: Blood Clots, Stroke, Heart Attack
Thursday, August 24, 2017
Home   |   DVT/PE   |   Blood Clots   |   Coumadin/Warfarin   |   New Patients   |   Self Testing   |   Email List   |   Donate

Pick a Topic:

Find info on a:

We subscribe to the HONcode principles of the HON Foundation. Click to verify.
ClotCare complies with the HONcode standard for trustworthy health
information:
verify here.

ClotCare is a member of the Coalition to Prevent Deep Vein Thrombosis (DVT Coalition)  ClotCare is a member organization of the Coalition to Prevent Deep Vein Thrombosis. Click here to learn more about the Coalition to Prevent Deep Vein Thrombosis and DVT Awareness Month, which is held each March.

Bextra Pulled from Market & Warnings Added to ALL NSAIDs

Marie B. Walker
April, 2005

Today (April 7, 2005), the FDA announced that it has asked Pfizer to pull Bextra (valdecoxib) from the market. According to the FDA's statement, Bextra is being pulled because "the overall risk versus benefit profile for the drug is unfavorable."1 Pfizer has agreed to comply with the FDA's request, but intends to have further discussion with the FDA on this issue.

The FDA has also asked Pfizer to provide a boxed warning on its drug Celebrex that highlights "the potential for increased risk of cardiovascular (CV) events and gastrointestinal (GI) bleeding associated with [its] use."1 The FDA is asking all manufacturers of NSAIDs to provide this same warning on their own NSAID labels. Makers of over-the-counter NSAIDs are being asked to include information on their labels about the increased risk of cardiovascular events and gastrointestinal bleeding as well as a warning about potential skin reactions. The prescription NSAID labels already contain a warning about potential skin reactions.

A list of prescription and non-prescription drugs in this class (NSAIDs) can be found at http://www.fda.gov/cder/drug/infopage/cox2/default.htm

1. The FDA's news release on changes to NSAIDs is available at http://www.fda.gov/bbs/topics/news/2005/NEW01171.html.

Ask a question about blood clots or anticoagulant medications Have questions? Ask ClotCare. Send questions by email to webmaster@clotcare.org.

ClotCare is a 501(c)(3) non-profit organization generously supported by your tax-deductible donations and grants from our industry supporters.

Blood Clot Activities Calendar

New Postings:

Click here to view full list of new postings
ClotCare Home | New Postings | Patient Postings | Clinician Postings | Join Our Email List | Useful Web Links
CE Opportunities | Training Programs | DVT & PE Stories | Editorial Board | Financial Support
About ClotCare | DVT Coalition | Donate to ClotCare | Contact Us
Key topics discussed on ClotCare include: Blood Clots | Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE) | Atrial Fibrillation (A. Fib or AF) | Heart Attack | Stroke | Transient Ischemic Attack (TIA) | Mini Stroke | Bleeding Complications | Vascular Surgery | Surgical Blood Clot Removal | Warfarin | Coumadin | Lovenox | Low Molecular Weight Heparin (LMWH) | Heparin | Anticoagulants | Plavix | Aspirin | Antiplatelets | Blood Thinners
Copyright 2000-2014 by ClotCare. All rights reserved.
Terms, Conditions, & Privacy | Image Copyright Information
19260 Stone Oak Parkway, Suite 101 | San Antonio, TX 78258 | 210-495-4335
Send comments to webmaster@clotcare.org.
Thursday, August 24, 2017